Literature DB >> 30995089

Radioligand Therapy With 177Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.

Madhav Prasad Yadav1, Sanjana Ballal1, Ranjit Kumar Sahoo2, Sada Nand Dwivedi3, Chandrasekhar Bal1.   

Abstract

OBJECTIVE. Several clinical studies have shown the efficacy of 177Lu-labeled prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) for metastatic castration-resistant prostate cancer (mCRPC). The purpose of this article is to present results of a systematic review and meta-analysis aimed at compiling and outlining efficacy and safety data on 177Lu-PSMA RLT for mCRPC across all studies published to date. CONCLUSION. The results of the systematic review and meta-analysis suggest that 177Lu-PSMA RLT is an effective treatment of advanced-stage mCRPC that is refractory to standard therapeutic options and that it has a low toxicity profile. High-level evidence from randomized control trials is crucial for confirming the effectiveness of 177Lu-PSMA RLT and for instituting this therapy in the routine clinical care of patients with mCRPC.

Entities:  

Keywords:  Lu-PSMA; castration-resistant prostate cancer; efficacy; lutetium-177; metastasis; prostate-specific membrane antigen; radioligand therapy; safety

Year:  2019        PMID： 30995089     DOI： 10.2214/AJR.18.20845

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN： 0361-803X            Impact factor:   3.959


  31 in total

1.  EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT).

Authors:  Clemens Kratochwil; Wolfgang Peter Fendler; Matthias Eiber; Richard Baum; Murat Fani Bozkurt; Johannes Czernin; Roberto C Delgado Bolton; Samer Ezziddin; Flavio Forrer; Rodney J Hicks; Thomas A Hope; Levant Kabasakal; Mark Konijnenberg; Klaus Kopka; Michael Lassmann; Felix M Mottaghy; Wim Oyen; Kambiz Rahbar; Heiko Schöder; Irene Virgolini; Hans-Jürgen Wester; Lisa Bodei; Stefano Fanti; Uwe Haberkorn; Ken Herrmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-22       Impact factor: 9.236

2.  Letter to the Editor re: Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake.

Authors:  M C F Cysouw; B H E Jansen; M Yaqub; J Voortman; A N Vis; R J A van Moorselaar; O S Hoekstra; R Boellaard; D E Oprea-Lager
Journal:  Mol Imaging Biol       Date:  2020-02       Impact factor: 3.488

3.  A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.

Authors:  Mohammad S Sadaghiani; Sara Sheikhbahaei; Rudolf A Werner; Kenneth J Pienta; Martin G Pomper; Lilja B Solnes; Michael A Gorin; Nae-Yuh Wang; Steven P Rowe
Journal:  Eur Urol       Date:  2021-04-08       Impact factor: 20.096

4.  Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort.

Authors:  Jeremie Calais; Andrei Gafita; Matthias Eiber; Wesley R Armstrong; Jeannine Gartmann; Pan Thin; Kathleen Nguyen; Vincent Lok; Laura Gosa; Tristan Grogan; Rouzbeh Esfandiari; Martin Allen-Auerbach; Andrew Quon; Shadfar Bahri; Pawan Gupta; Linda Gardner; David Ranganathan; Roger Slavik; Magnus Dahlbom; Ken Herrmann; Ebrahim Delpassand; Wolfgang P Fendler; Johannes Czernin
Journal:  J Nucl Med       Date:  2021-05-20       Impact factor: 10.057

Review 5.  Imaging of Prostate Cancer.

Authors:  Heinz-Peter Schlemmer; Bernd Joachim Krause; Viktoria Schütz; David Bonekamp; Sarah Marie Schwarzenböck; Markus Hohenfellner
Journal:  Dtsch Arztebl Int       Date:  2021-10-22       Impact factor: 8.251

6.  Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

Authors:  Oliver Sartor; Johann de Bono; Kim N Chi; Karim Fizazi; Ken Herrmann; Kambiz Rahbar; Scott T Tagawa; Luke T Nordquist; Nitin Vaishampayan; Ghassan El-Haddad; Chandler H Park; Tomasz M Beer; Alison Armour; Wendy J Pérez-Contreras; Michelle DeSilvio; Euloge Kpamegan; Germo Gericke; Richard A Messmann; Michael J Morris; Bernd J Krause
Journal:  N Engl J Med       Date:  2021-06-23       Impact factor: 91.245

Review 7.  More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond.

Authors:  Anniina Hyväkkä; Verneri Virtanen; Jukka Kemppainen; Tove J Grönroos; Heikki Minn; Maria Sundvall
Journal:  Cancers (Basel)       Date:  2021-05-07       Impact factor: 6.639

8.  Evaluation of the PSMA-Binding Ligand 212Pb-NG001 in Multicellular Tumour Spheroid and Mouse Models of Prostate Cancer.

Authors:  Vilde Yuli Stenberg; Roy Hartvig Larsen; Li-Wei Ma; Qian Peng; Petras Juzenas; Øyvind Sverre Bruland; Asta Juzeniene
Journal:  Int J Mol Sci       Date:  2021-05-01       Impact factor: 5.923

9.  Correlation of an Index-Lesion-Based SPECT Dosimetry Method with Mean Tumor Dose and Clinical Outcome after 177Lu-PSMA-617 Radioligand Therapy.

Authors:  Friederike Völter; Lena Mittlmeier; Astrid Gosewisch; Julia Brosch-Lenz; Franz Josef Gildehaus; Mathias Johannes Zacherl; Leonie Beyer; Christian G Stief; Adrien Holzgreve; Johannes Rübenthaler; Clemens C Cyran; Guido Böning; Peter Bartenstein; Andrei Todica; Harun Ilhan
Journal:  Diagnostics (Basel)       Date:  2021-03-03

10.  Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312).

Authors:  Jeremie Calais; Johannes Czernin; Pan Thin; Jeannine Gartmann; Kathleen Nguyen; Wesley R Armstrong; Martin Allen-Auerbach; Andrew Quon; Shadfar Bahri; Pawan Gupta; Linda Gardner; Magnus Dahlbom; Beilei He; Rouzbeh Esfandiari; David Ranganathan; Ken Herrmann; Matthias Eiber; Wolfgang P Fendler; Ebrahim Delpassand
Journal:  J Nucl Med       Date:  2021-07-16       Impact factor: 10.057
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.